Insight Molecular Diagnostics (IMDX) Research & Development (2015 - 2026)

Insight Molecular Diagnostics (IMDX) has 12 years of Research & Development data on file, last reported at $5.0 million in Q1 2026.

• Quarterly Research & Development rose 69.39% year-over-year to $5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.9 million (up 71.67% YoY) and the FY2025 annual result came in at $15.9 million, up 61.6% from the prior year.
• Research & Development declined to $5.0 million in Q1 2026 per IMDX's latest filing, from $5.8 million in the prior quarter.
• The five-year high for Research & Development was $5.8 million in Q4 2025, with the low at $1.4 million in Q4 2022.
• Average Research & Development over 5 years is $2.8 million, with a median of $2.4 million recorded in 2022.
• Year-over-year, Research & Development plunged 69.98% in 2022 and surged 158.26% in 2025.
• Insight Molecular Diagnostics' Research & Development stood at $1.4 million in 2022, then surged by 84.83% to $2.5 million in 2023, then slipped by 11.39% to $2.3 million in 2024, then jumped by 158.26% to $5.8 million in 2025, then fell by 15.03% to $5.0 million in 2026.
• Business Quant data shows IMDX's Research & Development at $5.0 million in Q1 2026, $5.8 million in Q4 2025, and $3.9 million in Q3 2025.